Home » Stocks » AYLA

Ayala Pharmaceuticals, Inc. (AYLA)

Stock Price: $13.15 USD 0.05 (0.38%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 167.39M
Revenue (ttm) 3.08M
Net Income (ttm) n/a
Shares Out 12.66M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $13.15
Previous Close $13.10
Change ($) 0.05
Change (%) 0.38%
Day's Open 12.99
Day's Range 12.70 - 13.90
Day's Volume 34,693
52-Week Range 8.80 - 15.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 days ago

Ayala Pharmaceuticals (AYLA) saw a big move last session, as its shares jumped more than 13% on the day, amid huge volumes.

GlobeNewsWire - 1 week ago

REHOVOT, Israel and WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing ...

GlobeNewsWire - 2 weeks ago

REHOVOT, Israel and WILMINGTON, Del., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing ...

GlobeNewsWire - 2 weeks ago

- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study -

Insider Monkey - 1 month ago

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion t...

GlobeNewsWire - 2 months ago

- Presented N ew P ositive I nterim D ata from 4mg C ohort of Phase 2 ACCURACY S tudy of AL101 for the T reatment of R/M ACC at European Society for Medical Oncology 2020 -

GlobeNewsWire - 2 months ago

REHOVOT, Israel and WILMINGTON, Del., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing ...

Seeking Alpha - 2 months ago

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular wa...

Other stocks mentioned: FUBO, GAN, INTZ, KC, KRON, SPRB, STTK
GlobeNewsWire - 4 months ago

– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate

GlobeNewsWire - 4 months ago

REHOVOT, Israel and WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializi...

GlobeNewsWire - 4 months ago

REHOVOT, Israel and WILMINGTON, Del., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializi...

GlobeNewsWire - 5 months ago

REHOVOT, Israel and WILMINGTON, Del., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (the Company or Ayala), a clinical-stage oncology company focused on develo...

GlobeNewsWire - 5 months ago

– New interim data from Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC to be presented at ESMO 2020 –

GlobeNewsWire - 5 months ago

REHOVOT, Israel and WILMINGTON, Del., July 27, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializin...

GlobeNewsWire - 7 months ago

– Completed upsized initial public offering raising a total of $59.1 million in gross proceeds

Benzinga - 7 months ago

The Phase 2 study of Ayala Pharmaceuticals Inc’s (NASDAQ: AYLA) AL101 candidate is scheduled to begin in the back half of this year.

About AYLA

Ayala Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule G... [Read more...]

Industry
Biotechnology
IPO Date
May 8, 2020
CEO
Dr. Roni Mamluk
Employees
31
Stock Exchange
NASDAQ
Ticker Symbol
AYLA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for AYLA stock is "Buy." The 12-month stock price forecast is 21.60, which is an increase of 64.26% from the latest price.

Price Target
$21.60
(64.26% upside)
Analyst Consensus: Buy